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Abstract
Congestive heart failure (CHF) refractory to pharmacological therapy is a growing medical 
problem. Renal sodium and water retention remains a key event in the pathogenesis of the 
disease progression and episodes of severe cardiac decompensation, being also the leading cau-
se of high hospitalization rates and an important risk factor for worsening kidney function and 
chronic kidney disease (CKD). The two conditions: CHF and CKD form a vicious circle, with 
a tremendous escalation of complications and mortality. In this clinical situation, peritoneal 
ultrafiltration (PUF) may be a reasonable choice for long-term treatment of selected patients 
with end-stage CHF, especially for those with contradictions to heart transplantation. Several 
observational studies have demonstrated its efficacy and safety in this population. Fluid and 
sodium removal via peritoneal cavity resulted in significant plasma volume reduction, norma-
lization of serum sodium and restoration of diuretic responsiveness, as well as an improvement 
in New York Heart Association functional class, reduction of hospitalization and readmission 
rates. The complications are typical for peritoneal dialysis (catheter exit site infections, peri-
tonitis and fluid leaks) but they are much more rare with 1 instead of 4 exchanges per day, 
and it seems that at least in case of PUF with 1–2 peritoneal exchanges a day, the benefits of 
the therapy outweigh the risks. However, as the studied groups were small, larger multicenter 
randomized trials are necessary to develop precise recommendations regarding clinical aspects 
of PUF in severe CHF and indications for its use. (Cardiol J 2014; 21, 2: 115–120)
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Introduction
It is estimated that 1–2.5% of adult population 
suffers from congestive heart failure (CHF), while 
in patients over 70 years of age this proportion 
exceeds 10% [1]. Although the last decades brou-
ght a considerable improvement in the therapy of 
patients with CHF, leading to a reduction in their 
mortality and morbidity, the long-term prognosis 
remains poor [2].
Advanced CHF is often accompanied by 
varying degrees of chronic kidney disease (CKD). 
Coexistence of both pathologies is referred to as 
cardiorenal syndrome type 2 [3]. Reduced cardiac 
output leads to a reduction in the glomerular filtra-
tion rate (GFR), a strong stimulus activating neu-
rohormonal adaptation axes (renin–angiotensin– 
–aldosterone, noradrenergic system, vasopressin 
secretion) with renal sodium and water retention, 
simultaneously persisting renal hypoperfusion 
with an increase in renal vascular resistance sti-
mulating the development of progressive ischemic 
nephropathy. On the other hand, consequences of 
CKD that appear as the disease advances, such 
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as: anemia, inflammation and cardiovascular calci-
fications, contribute considerably to progression 
of CHF. A vicious cycle is induced, in which each 
condition (CHF and CKD) exacerbates and stimulates 
the progression of the other. Heart failure usually 
advances more rapidly, and constitutes the leading 
cause of death before the development of uremia 
requiring renal replacement therapy [2, 3].
About 5% of patients with CHF progress to its 
end-stage stadium. Sodium and water retention, 
fundamental to this progression, remains also one of 
the main causes (> 90%) of hospitalizations [2, 4]. 
End-stage CHF is characterized by a significant 
resistance to pharmacological treatment, especially 
to diuretics. This is caused, among other things, by 
an impairment of drug delivery to renal tubules due 
to both hypoperfusion and edema of kidneys, which 
disrupts the hemodynamic balance in the renal glo-
merulus with a significant reduction in GFR [5, 6]. 
In order to overcome this resistance, a transient use 
of intravenous loop diuretics is necessary. Unfortu-
nately, it is not always fully effective and often leads 
to worsening the kidney functioning. In about 40% 
of patients, at the time of discharge from hospital 
fluid overload of varying degrees persists and al-
most 30% of them are readmitted within a month 
[4, 7]. Mortality in this group is dramatically high; 
it is estimated to reach 40–50% within 6 months 
[2, 7, 8]. Unfortunately, due to advanced age and 
comorbidities, most of these patients have contra-
indications to non-pharmacological treatment, such 
as heart transplantation, resynchronization therapy 
or other surgical methods. Therefore, it is of great 
importance to establish a treatment strategy that 
would ensure the most effective volume reduction 
without the adverse influence on renal function and 
patients hemodynamics, improving patient’s qua-
lity of life by reducing symptoms and frequency of 
hospitalizations, and — maybe — giving a chance 
for better prognosis.
Ultrafiltration
In some patients with considerable fluid over-
load and significant loop diuretic resistance, ultra-
filtration (UF) may be the only effective method of 
removing the excess fluid. Such a purely mechani-
cal method of reducing intravascular volume leads 
to lowering the systemic venous pressure as well 
as the pressure in pulmonary circulation accompa-
nied by improvement in hemodynamic parameters 
and decreased adverse influence of neurohormonal 
activation on cardiac and renal function. It has been 
demonstrated, that in patients with CHF receiving 
UF, plasma renin, norepinephrine and aldosterone 
concentrations are lower as long as 90 days after 
treatment compared with those receiving diuretics 
[9]. Simultaneously, UF improves hemodynamic 
conditions within the renal glomerulus by redu-
cing parenchymal edema, accompanied by GFR 
elevation, increased diuresis and restoration of 
sensitivity to diuretics [9–11]. In a study by Guazzi 
et al. [12] of 22 patients with CHF, the use of UF 
was associated with a significant diuresis increase 
(852 vs. 2132 mL/d) as well as urinary sodium excre-
tion (39 vs. 137 mmol/d) 24 h after the therapy.
In comparison to diuretic therapy, UF is more 
effective in net sodium removal, as the ultrafiltrate 
is isonatremic and iso-osmolar compared with plas-
ma as opposed to the hypotonic urine produced in 
response to diuretics [13]. Therefore, UF removes 
more sodium and less potassium, allowing to avoid 
electrolyte disturbances often observed during tre-
atment with diuretics. Finally, contrary to loop diu-
retics, which increase sodium influx into the distal 
tubule through inhibition of Na-K-2Cl channels, UF 
— sparing exposure of the renal tubules to sodium 
— does not trigger to such extent the maladaptive 
tubule-glomerular feedback with paracrine effects 
on local vasculature [6, 14].
There are two types of UF: extracorporeal 
and peritoneal.
Extracorporeal ultrafiltration
Extracorporeal UF performed with an artificial 
kidney utilizes the mechanism of water removal 
from plasma through a semipermeable membrane 
due to the transmembrane pressure gradient. For 
many years, the so-called isolated extracorporeal 
UF has been used in dialysis centers for various 
extrarenal reasons, particularly in patients with 
massive generalized edema, usually occurring in 
the course of nephrotic syndrome. In acute CHF 
decompensation it may be a life-saving treatment 
method; it can also contribute to shortening the 
hospitalization time [10, 15–17]. However, ex-
tracorporeal UF is associated with the need to 
gain vascular access, administration of systemic 
anticoagulation, use of special devices (artificial 
kidney, filters, bloodlines), and presence of qualified 
medical personnel. Moreover, it may be conducted 
exclusively in a hospital environment or even in 
intensive care units in case of hemodynamically 
unstable patients. Excessively rapid fluid removal 
from the intravascular space may induce episodes 
of severe hypotension with organ hypoperfusion, 
including central nervous system, heart or kidneys.
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While this method may be useful in patients 
with severe cardiovascular decompensation, its 
long-term use may be problematic. That would 
mean either the necessity of permanent hospi-
talization or performing the procedure 3–4 times 
a week, as in case of chronic dialysis for end-stage 
renal disease. It poses a risk of significant fluctu-
ations in volume status with augmentation of heart 
failure symptoms between treatments and hypo-
tension during the procedure, hindering adequate 
water removal. These phenomena are often ob-
served in chronically hemodialyzed patients and are 
thought to contribute considerably to progression 
of heart disease. Peritoneal ultrafiltration (PUF) 
with or without peritoneal dialysis (PD) provides 
a chance to avoid such problems.
Peritoneal ultrafiltration
Chronic PD is a renal replacement therapy 
conducted by the patient (or a family member) 
under home conditions. Due to a specific structure 
of densely vascularized peritoneum, it takes advan-
tage of the fact that, after filling peritoneal cavity 
with an osmotically active fluid (containing glucose, 
amino acids or icodextrin) molecules with small- or 
medium-molecular mass (through diffusion) and 
water (through convection) pass from patient’s 
blood into the peritoneal cavity.
Effectiveness of both processes depends on 
patient-specific properties of peritoneal membrane 
on one hand, but on the other, it may be widely 
modified through various methods of dialysis fluid 
application (manual or automatic), its volume, 
frequency of exchanges as well as the type and 
concentration of an osmotically active substance. 
Fluids for PD do not contain potassium, which 
minimizes the risk of hyperkalemia and allows  op-
timization of therapy with angiotensin converting 
enzyme inhibitors or an aldosterone antagonists. 
Continuous slow character of PUF does not cause 
significant blood volume fluctuations and facilita-
tes hemodynamic stability, while constant evacu-
ation of fluid from the peritoneal cavity maintains 
intra-abdominal pressure at a relatively low level, 
allowing to sustain the response to diuretics and 
preserve the renal function. Additionally, a poten-
tial benefit may involve transperitoneal removal 
of inflammatory molecules and other cardio-de-
pressants, improving myocardial function, as well 
as prevention of ascites, minimizing discomfort, 
and lowering the risk of spontaneous bacterial 
peritonitis [11, 18]. Nevertheless, these issues 
need further investigation.
Dialysis fluids containing icodextrin may be 
of particular interest with regard to treatment of 
patients with heart failure. It is a high-molecular 
mass (about 17 kDa) glucose polymer, iso-osmolar 
to blood plasma, which induces UF through col-
loidal osmosis. Due to minimal diffusion into the 
systemic circulation it leads to constant high UF 
regardless of peritoneal membrane transportation 
properties. So far it has been the only substance 
that can provide UF when it stays in the peritoneal 
cavity for longer than 8 h. Experimental treatments 
in patients with end-stage renal disease indicate 
that icodextrin is more effective than glucose with 
regard to systemic extravascular water reduction 
and this effect is proportional the to state of hy-
dration [19]. It is also more effective in removing 
medium-size compounds (e.g. leptin) and finally, 
as opposed to glucose, does not cause metabolic 
disorders (hyperinsulinemia, dyslipidemia) [19].
Peritoneal dialysis was first successfully used 
in treatment of heart failure over 60 years ago 
[20]. Since then, several case reports and case 
series have been published, demonstrating the 
beneficial effects of PD/PUF in patients with severe 
treatment-resistant CHF, regardless of the degree 
of renal impairment. Unfortunately, they are uncon-
trolled and the groups studied are small. Patients 
with coexisting renal failure may be treated with 
intermittent PD [21], continuous ambulatory PD 
[22–26] or automated PD [27–30], while in those 
without significant impairment of renal function 
— a single nightly exchange (PUF) with osmotic 
agent (optimally icodextrin) is sufficient [31–35]. In 
the vast majority of cases PD/PUF was performed 
in patients with advanced CHF and symptoms of 
cardiorenal syndrome as an addition to standard 
therapy. It usually concerned elderly patients with 
numerous comorbidities and various degrees of re-
nal impairment, disqualified from heart transplan-
tation and refractory to pharmacological treatment. 
In some centers, extracorporeal UF was initially 
performed for quick reduction of fluid overload 
[28, 29, 32–35], while in the others therapy was 
commenced with PUF or PD. PUF/PD dose was 
matched to individual patient’s needs in order to 
obtain optimal UF on one hand, while achieving 
adequate balancing of metabolic disturbances as-
sociated with renal impairment on the other.
The most important clinical studies on PD or 
an isolated PUF are presented in Table 1. The bene-
fits obtained were similar regardless of the applied 
method (PUF or PD), although different studies 
analyzed various parameters. Commencement of 
PUF/PD was associated with improved response 
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to diuretics, allowing for a significant (by as much 
as 50%) dose reduction and increased diuresis 
with stable renal function during the observation 
period [26, 29, 32–35]. The effect of continuous, 
slow removal of water and sodium excess via pe-
ritoneal cavity may be of significance here, as it 
facilitates gradual reduction of extracellular volume 
and, subsequently, maintenance of normovolemia 
and neurohormonal stabilization. That would 
be indicated by, as observed by some authors, 
a decrease in plasma renin activity, as well as in se-
rum concentrations of aldosterone and natriuretic 
peptides: atrial and B-type [22, 29]. Reduction or 
disappearance of clinical symptoms, accompanied 
by functional improvement in New York Heart 
Association (NYHA) class [22, 23, 25, 28, 30, 31, 
33, 34], with better exercise capacity [26] was 
observed in a great majority of patients. In some 
reports, this spectacular clinical improvement 
was accompanied by an increase in heart ejection 
fraction [25, 28, 31, 34], or even — by a reduction 
in pulmonary artery pressure [24, 26, 34], which 
could be of great significance, giving some patients 
a chance to re-qualify for heart transplantation [22, 
23]. In such patients PUF could constitute a “brid-
ge therapy” while awaiting heart transplantation, 
simultaneously reducing the risk of organ damage 
that could disqualify them from such a procedure.
The spectacular, 6–12-fold reduction in the 
frequency and duration of hospitalization, remains 
a fundamental advantage of PUF/PD [23, 24, 26–28, 
30–34]. This effect is particularly significant in pa-
tients who use it as palliative therapy with regard 
to their quality of life as well as healthcare costs 
[26, 34]. Pharmacoeconomic analysis conducted 
by authors from Spain revealed a nearly 4-fold 
reduction in yearly costs with application of PUF 
in comparison to standard therapy [34].
PUF is a relatively safe therapy. The potential 
side effects are the same as for standard PD, in-
cluding catheter related infections and mechanical 
problems (fluid leaks), but they are much more rare 
with 1 or 2 exchanges per day [23, 28, 29, 32–34]. 
The use of 1 instead of 4 peritoneal exchanges redu-
ced significantly the risk of peritonitis and exit-site 
infections. In the case series of 17 patients treated 
by PUF reported by Sanchez et al. [34], peritonitis 
was the only technique complication, being 28 ti-
mes rarer than in Spanish PD Unit Registry (0.02 
vs. 0.56 episodes/patient/year at risk; p = 0.008). 
Mechanical problems (leaks, hernias) are mostly 
related to the increase of intra-abdominal pressure 
during the exchange. Pericatheter leaks usually 
occur after an acute start of PD, and they can be 
prevented by delaying PUF for 10–14 days after 
catheter insertion. Before starting the patient 
on PUF the contradictions to PD must be ruled 
out (Table 2), and a careful search for a presence 
of hernias has to be performed, which, if found, 
should be repaired. In many cases it can be done 
simultaneously with catheter insertion under local 
anesthesia.
It is difficult to say whether broadening the 
standard therapy to include PUF would significan-
tly change the natural course of the disease and 
improve patients’ survival. In a recent analysis 
of Polish Registry of Patients Referred for Heart 
Transplantation (POLKARD HF) only symptoms 
compatible with NYHA class IV, persisting despi-
te an adequate treatment were related to a bad 
prognosis [8]. However, available data acquired 
from non-randomized trials on small numbers of 
patients and with short observation times do not 
allow drawing any conclusions. It is only possible 
to suggest that, since a 6-month mortality among 
patients resistant to treatment exceeds 50%, any 
method that could potentially reverse this drama-
tically poor prognosis is highly desirable [2, 7]. In 
this context, yearly mortality of 10–15% reported 
by some authors in a group of patients treated with 
PUF [28, 30] should be considered a satisfactory 
improvement in survival. Undoubtedly, this effect 
should be assessed in controlled, randomized 
clinical trials.
Conclusions
All the data gathered to date from obser-
vational studies on the role of PUF as palliative 
treatment adjuvant to standard pharmacotherapy 
Table 2. Contradictions to peritoneal ultrafiltration.
•	History of abdominal surgeries with extensive  
adhesions or ostomies
•	Patient’s/caregiver’s incapability of performing  
the procedure, poor hygiene
•	Uncorrectable mechanical defects that increase 
the risk of complications (e.g. surgically  
irreparable hernia)
•	Abdominal abscess
•	Severe inflammatory bowel disease, active  
ischemic bowel disease, recurrent diverticulitis
•	Morbid obesity
•	Advanced chronic obstructive pulmonary 
disease 
•	Extensive abdominal wall infection 
•	Recent history (4–6 months) of abdominal  
vascular surgery with prostheses
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in patients with severe CHF refractory to optimal 
treatment are encouraging and indicate their effi-
cacy as well as safety. Given that the complications 
such as peritonitis or leaks are relatively rare, it 
seems that the benefits of the therapy far outweigh 
its risks. The greatest benefit is, according to the 
previous studies, improved quality of live as me-
asured by spectacular reduction in the frequency 
of hospitalizations. Only the results of multicen-
ter, randomized trials may answer the question 
whether PUF could extend patient’s lifespan. It is 
also important to determine which patients could 
potentially benefit from this type of therapy the 
most and what could be the value of this method 
as a “bridge to transplantation” therapy.
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